Close

Amgen (AMGN) Announces Receipt of Positive EMA CHMP Opinion on Kyprolis as Relapsed Multiple Myeloma Treatment

May 27, 2016 7:30 AM EDT Send to a Friend
Amgen (Nasdaq: AMGN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login